Francesco Luzzaro

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6355711/publications.pdf

Version: 2024-02-01

112 papers 4,543 citations

35 h-index 110387 64 g-index

116 all docs

116 docs citations

116 times ranked

4666 citing authors

#	Article	IF	Citations
1	Humoral and T-cell response to SARS-CoV-2 mRNA BNT162b2 vaccination in a cohort of kidney transplant recipients and their cohabitant living kidney donor partners. CKJ: Clinical Kidney Journal, 2022, 15, 820-821.	2.9	3
2	Sustained humoral response 6 months after the anti-SARS-CoV-2 mRNA-BNT162b2 vaccine in haemodialysis patients: should booster vaccine doses be given to all patients at the same time?. CKJ: Clinical Kidney Journal, 2022, 15, 1012-1014.	2.9	0
3	Antimicrobial Susceptibility, Virulence, and Genomic Features of a Hypervirulent Serotype K2, ST65 Klebsiella pneumoniae Causing Meningitis in Italy. Antibiotics, 2022, 11, 261.	3.7	8
4	Anaerobic bloodstream infections in Italy (ITANAEROBY): A 5-year retrospective nationwide survey. Anaerobe, 2022, 75, 102583.	2.1	13
5	Simultaneous gut colonization by Klebsiella grimontii and Escherichia coli co-possessing the blaKPC-3-carrying pQil plasmid. European Journal of Clinical Microbiology and Infectious Diseases, 2022, 41, 1087-1091.	2.9	3
6	A Two Amino Acid Duplication, L167E168, in the \hat{I} ©-Loop Drastically Decreases Carbapenemase Activity of KPC-53, a Natural Class A \hat{I}^2 -Lactamase. Antimicrobial Agents and Chemotherapy, 2022, 66, .	3.2	2
7	the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infective Therapy (SITA), the Italian Group for Antimicrobial Stewardship (GISA), the Italian Association of Clinical Microbiologists (AMCLI) and the Italian Society of Microbiology (SIM). International Journal	2.5	36
8	Polypyridine ligands as potential metallo-Î ² -lactamase inhibitors. Journal of Inorganic Biochemistry, 2021, 215, 111315.	3.5	7
9	Trends in the Incidence and Antibiotic Resistance of Enterococcal Bloodstream Isolates: A 7-Year Retrospective Multicenter Epidemiological Study in Italy. Microbial Drug Resistance, 2021, 27, 529-535.	2.0	5
10	EUCAST rapid antimicrobial susceptibility testing of blood cultures positive for Escherichia coli or Klebsiella pneumoniae: experience of three laboratories in Italy. Journal of Antimicrobial Chemotherapy, 2021, 76, 1110-1112.	3.0	2
11	The humoral immune response to SARS-CoV-2 mounts and is durable in symptomatic haemodialysis patients. Nephrology Dialysis Transplantation, 2021, 36, 1132-1134.	0.7	5
12	Comparing BioFire FilmArray BCID2 and BCID Panels for Direct Detection of Bacterial Pathogens and Antimicrobial Resistance Genes from Positive Blood Cultures. Journal of Clinical Microbiology, 2021, 59, .	3.9	30
13	An XDR Proteus vulgaris isolate hosting a novel blaNDM-1- and armA-carrying plasmid. Journal of Antimicrobial Chemotherapy, 2021, 76, 1938-1941.	3.0	1
14	Resistance to ceftazidime/avibactam in infections and colonisations by KPC-producing Enterobacterales: a systematic review of observational clinical studies. Journal of Global Antimicrobial Resistance, 2021, 25, 268-281.	2.2	62
15	Whole-Genome Sequencing Investigation of a Large Nosocomial Outbreak Caused by ST131 H30Rx KPC-Producing Escherichia coli in Italy. Antibiotics, 2021, 10, 718.	3.7	7
16	Zidovudine in synergistic combination with fosfomycin: an in vitro and in vivo evaluation against multidrug-resistant Enterobacterales. International Journal of Antimicrobial Agents, 2021, 58, 106362.	2.5	13
17	The Revival of Aztreonam in Combination with Avibactam against Metallo-β-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases. Antibiotics, 2021, 10, 1012.	3.7	73
18	Incidence of SARS-CoV-2 infection in health care workers from Northern Italy based on antibody status: immune protection from secondary infection- A retrospective observational case-controlled study. International Journal of Infectious Diseases, 2021, 109, 199-202.	3.3	20

#	Article	IF	Citations
19	Successful prolonged cefiderocol treatment of a chronic left pleural empyema caused by Pseudomonas aeruginosa in a patient affected by COVID-19: a case report. Journal of Global Antimicrobial Resistance, 2021, 27, 157-159.	2.2	7
20	Antimicrobial Activity of Aztreonam in Combination with Old and New \hat{I}^2 -Lactamase Inhibitors against MBL and ESBL Co-Producing Gram-Negative Clinical Isolates: Possible Options for the Treatment of Complicated Infections. Antibiotics, 2021, 10, 1341.	3.7	13
21	Emergence of Haemophilus parainfluenzae resistant to third-generation cephalosporins in Italy: potential role of PBP3 and PBP5 substitutions in high-level resistance. International Journal of Antimicrobial Agents, 2020, 56, 106159.	2.5	3
22	Recommendations for the surveillance of multidrug-resistant bacteria in Italian long-term care facilities by the GLISTer working group of the Italian Association of Clinical Microbiologists (AMCLI). Antimicrobial Resistance and Infection Control, 2020, 9, 106.	4.1	11
23	Rapid Increase of CTX-M-Producing Shigella sonnei Isolates in Switzerland Due to Spread of Common Plasmids and International Clones. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	22
24	KPC-53, a KPC-3 Variant of Clinical Origin Associated with Reduced Susceptibility to Ceftazidime-Avibactam. Antimicrobial Agents and Chemotherapy, 2020, 65, .	3.2	19
25	Zinc Chelators as Carbapenem Adjuvants for Metallo- \hat{l}^2 -Lactamase-Producing Bacteria: <i>In Vitro</i> and <i>In Vivo</i> Evaluation. Microbial Drug Resistance, 2020, 26, 1133-1143.	2.0	17
26	Results of the Italian infection-Carbapenem Resistance Evaluation Surveillance Trial (iCREST-IT): activity of ceftazidime/avibactam against Enterobacterales isolated from urine. Journal of Antimicrobial Chemotherapy, 2020, 75, 979-983.	3.0	12
27	<i>In vitro</i> activity of ceftazidime/avibactam against clinical isolates of ESBL-producing <i>Enterobacteriaceae</i> in Italy. Journal of Chemotherapy, 2019, 31, 195-201.	1.5	4
28	Simplified Testing Method for Direct Detection of Carbapenemase-Producing Organisms from Positive Blood Cultures Using the NG-Test Carba 5 Assay. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	26
29	Role of place of acquisition and inappropriate empirical antibiotic therapy on the outcome of extended-spectrum β-lactamase-producing Enterobacteriaceae infections. International Journal of Antimicrobial Agents, 2019, 54, 49-54.	2.5	15
30	Characterisation of the first extended-spectrum \hat{l}^2 -lactamase (ESBL)-producing Shigella sonnei clinical isolate in Italy. Journal of Global Antimicrobial Resistance, 2019, 17, 58-59.	2.2	5
31	Novel vanA-carrying plasmid in a clinical isolate of Enterococcus avium. International Journal of Antimicrobial Agents, 2019, 53, 876-877.	2.5	2
32	Evaluation of EDTA- and DPA-Based Microdilution Phenotypic Tests for the Detection of MCR-Mediated Colistin Resistance in Enterobacteriaceae. Microbial Drug Resistance, 2019, 25, 494-500.	2.0	10
33	Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers. Journal of Antimicrobial Chemotherapy, 2018, 73, 664-671.	3.0	71
34	Deciphering the complete deletion of the mgrB locus in an unusual colistin-resistant Klebsiella pneumoniae isolate colonising the gut of a traveller returning from India. International Journal of Antimicrobial Agents, 2018, 51, 529-531.	2.5	12
35	Mother-to-child transmission of KPC-producing Klebsiella pneumoniae: potential relevance of a low microbial urinary load for screening purposes. Journal of Hospital Infection, 2018, 98, 314-316.	2.9	2
36	Whole-Genome Sequence of the First Extended-Spectrum \hat{I}^2 -Lactamase-Producing Strain of Salmonella enterica subsp. enterica Serovar Napoli. Microbiology Resource Announcements, 2018, 7, .	0.6	10

#	Article	IF	Citations
37	The EDTA-based disk-combination tests are unreliable for the detection of MCR-mediated colistin-resistance in Enterobacteriaceae. Journal of Microbiological Methods, 2018, 153, 31-34.	1.6	4
38	Emergence of CTX-M-1-producing Salmonella enterica serovar Napoli: A novel â€~enzyme–pathogen association' in the Italian extended-spectrum β-lactamase (ESBL) endemic context. Journal of Global Antimicrobial Resistance, 2018, 15, 101-102.	2.2	2
39	Multicenter prospective study on the prevalence of colistin resistance in Escherichia coli : relevance of mcr-1 -positive clinical isolates in Lombardy, Northern Italy. Infection and Drug Resistance, 2018, Volume 11, 377-385.	2.7	19
40	First report of NDM-1-producing Klebsiella pneumoniae imported from Africa to Italy: Evidence of the need for continuous surveillance. Journal of Global Antimicrobial Resistance, 2017, 8, 23-27.	2.2	20
41	Mother-To-Child Transmission of KPC Carbapenemase-Producing Klebsiella Pneumoniae at Birth. Pediatric Infectious Disease Journal, 2017, 36, 228-229.	2.0	15
42	Evaluation of a New Commercial Microarray Platform for the Simultaneous Detection of \hat{l}^2 -Lactamase and <i>mcr-1</i> and <i>mcr-2</i> Genes in Enterobacteriaceae. Journal of Clinical Microbiology, 2017, 55, 3138-3141.	3.9	33
43	An allelic variant of the PmrB sensor kinase responsible for colistin resistance in an Escherichia coli strain of clinical origin. Scientific Reports, 2017, 7, 5071.	3.3	42
44	Identification by mass spectrometry and automated susceptibility testing from positive bottles: a simple, rapid, and standardized approach to reduce the turnaround time in the management of blood cultures. BMC Infectious Diseases, 2017, 17, 749.	2.9	14
45	Evolving beta-lactamase epidemiology in Enterobacteriaceae from Italian nationwide surveillance, October 2013: KPC-carbapenemase spreading among outpatients. Eurosurveillance, 2017, 22, .	7.0	49
46	Evaluation of the in vitro activity of ceftobiprole against clinical isolates of Staphylococcus aureus. Microbiologia Medica, $2016, 31, \ldots$	0.1	0
47	Erysipelothrix rhusiopathiae Bacteremia without Endocarditis: Rapid Identification from Positive Blood Culture by MALDI-TOF Mass Spectrometry. A Case Report and Literature Review. Gastroenterology Insights, 2016, 8, 6368.	1.2	23
48	Review on colonization of residents and staff in Italian long-term care facilities by multidrug-resistant bacteria compared with other European countries. Antimicrobial Resistance and Infection Control, 2016, 5, 33.	4.1	27
49	Comparison of the in-house made Carba-NP and Blue-Carba tests: Considerations for better detection of carbapenemase-producing Enterobacteriaceae. Journal of Microbiological Methods, 2016, 122, 33-37.	1.6	19
50	First Detection of the $\langle i \rangle$ mcr- $1 \langle j \rangle$ Colistin Resistance Gene in Escherichia coli in Italy. Antimicrobial Agents and Chemotherapy, 2016, 60, 3257-3258.	3.2	74
51	Reporting epidemiology of antibiotic resistance. Microbiologia Medica, 2015, 30, .	0.1	3
52	Management of carbapenem resistant Klebsiella pneumoniae infections in stem cell transplant recipients: an Italian multidisciplinary consensus statement. Haematologica, 2015, 100, e373-e376.	3.5	44
53	<i>In Vitro</i> Activity of the Novel Antimicrobial Peptide Dendrimer G3KL against Multidrug-Resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2015, 59, 7915-7918.	3.2	70
54	Direct identification of microorganisms from positive blood cultures using the lysis-filtration technique and matrix assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS): a multicentre study. New Microbiologica, 2015, 38, 245-50.	0.1	18

#	Article	IF	Citations
55	Cross-Infection of Solid Organ Transplant Recipients by a Multidrug-Resistant Klebsiella pneumoniae Isolate Producing the OXA-48 Carbapenemase, Likely Derived from a Multiorgan Donor. Journal of Clinical Microbiology, 2014, 52, 2702-2705.	3.9	38
56	Epidemic Diffusion of OXA-23-Producing Acinetobacter baumannii Isolates in Italy: Results of the First Cross-Sectional Countrywide Survey. Journal of Clinical Microbiology, 2014, 52, 3004-3010.	3.9	64
57	Characterization of resistance mechanisms and genetic relatedness of carbapenem-resistant Acinetobacter baumannii isolated from blood, Italy. Diagnostic Microbiology and Infectious Disease, 2013, 75, 180-186.	1.8	30
58	Acquisition of plasmid-borne blaIMP-19 gene by a VIM-1-positive Pseudomonas aeruginosa of the sequence type 235 epidemic lineage. Journal of Antimicrobial Chemotherapy, 2013, 68, 722-724.	3.0	11
59	FIM-1, a New Acquired Metallo- \hat{l}^2 -Lactamase from a Pseudomonas aeruginosa Clinical Isolate from Italy. Antimicrobial Agents and Chemotherapy, 2013, 57, 410-416.	3.2	87
60	Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and Â-haemolytic streptococci collected from western European countries in 2011. Journal of Antimicrobial Chemotherapy, 2013, 68, 164-167.	3.0	35
61	Evaluation of brilliance CRE agar for the detection of carbapenem-resistant gram-negative bacteria. New Microbiologica, 2013, 36, 181-6.	0.1	5
62	Emergence and spread of a multidrug-resistant Acinetobacter baumannii clone producing both the carbapenemase OXA-23 and the 16S rRNA methylase ArmA. Journal of Medical Microbiology, 2012, 61, 653-661.	1.8	34
63	Epidemiology and genetic characteristics of extended-spectrum Â-lactamase-producing Gram-negative bacteria causing urinary tract infections in long-term care facilities. Journal of Antimicrobial Chemotherapy, 2012, 67, 2982-2987.	3.0	58
64	Microarray technology for yeast identification directly from positive blood cultures. A multicenter Italian experience. Medical Mycology, 2012, 50, 549-555.	0.7	9
65	Evaluation of the peptide nucleic acid fluorescence <i>in situ</i> hybridisation technology for yeast identification directly from positive blood cultures: an Italian experience. Mycoses, 2012, 55, 388-392.	4.0	25
66	Prevalence and epidemiology of microbial pathogens causing bloodstream infections: results of the OASIS multicenter study. Diagnostic Microbiology and Infectious Disease, 2011, 69, 363-369.	1.8	69
67	Escherichia coli ST131 Producing Extended-Spectrum Â-Lactamases Plus VIM-1 Carbapenemase: Further Narrowing of Treatment Options. Clinical Infectious Diseases, 2011, 52, 690-691.	5.8	26
68	Persistence of TEM-52/TEM-92 and SHV-12 Extended-Spectrum β-Lactamases in Clinical Isolates of Enterobacteriaceae in Italy. Microbial Drug Resistance, 2011, 17, 521-524.	2.0	12
69	Characterization of pABVA01, a Plasmid Encoding the OXA-24 Carbapenemase from Italian Isolates of <i>Acinetobacter baumannii</i> Antimicrobial Agents and Chemotherapy, 2009, 53, 3528-3533.	3.2	105
70	Spread of multidrug-resistant Proteus mirabilis isolates producing an AmpC-type β-lactamase: epidemiology and clinical management. International Journal of Antimicrobial Agents, 2009, 33, 328-333.	2.5	51
71	First Countrywide Survey of Acquired Metallo- \hat{l}^2 -Lactamases in Gram-Negative Pathogens in Italy. Antimicrobial Agents and Chemotherapy, 2008, 52, 4023-4029.	3.2	58
72	Spread in an Italian Hospital of a Clonal Acinetobacter baumannii Strain Producing the TEM-92 Extended-Spectrum β-Lactamase. Antimicrobial Agents and Chemotherapy, 2007, 51, 2211-2214.	3.2	39

#	Article	IF	CITATIONS
73	Characterization of the IncA/C plasmid pCC416 encoding VIM-4 and CMY-4 \hat{l}^2 -lactamases. Journal of Antimicrobial Chemotherapy, 2007, 60, 258-262.	3.0	30
74	Biochemical analysis of TEM-134, a new TEM-type extended-spectrum Â-lactamase variant produced in a Citrobacter koseri clinical isolate from an Italian hospital. Journal of Antimicrobial Chemotherapy, 2007, 60, 877-880.	3.0	8
75	Metallo- \hat{l}^2 -lactamases as emerging resistance determinants in Gram-negative pathogens: open issues. International Journal of Antimicrobial Agents, 2007, 29, 380-388.	2.5	134
76	Diagnostica delle ß-lattamasi a spettro esteso (ESBL) nelle Enterobacteriaceae: problemi e raccomandazioni nella realtà epidemiologica italiana. Microbiologia Medica, 2007, 22, .	0.1	2
77	Drug susceptibility testing of clinical isolates of streptococci and enterococci by the Phoenix automated microbiology system. BMC Microbiology, 2007, 7, 46.	3.3	7
78	CTX-M: changing the face of ESBLs in Europe. Journal of Antimicrobial Chemotherapy, 2006, 59, 165-174.	3.0	756
79	Trends in Production of Extended-Spectrum β-Lactamases among Enterobacteria of Medical Interest: Report of the Second Italian Nationwide Survey. Journal of Clinical Microbiology, 2006, 44, 1659-1664.	3.9	110
80	Performance in detection and reporting \hat{l}^2 -lactam resistance phenotypes in Enterobacteriaceae: a nationwide proficiency study in Italian laboratories. Diagnostic Microbiology and Infectious Disease, 2006, 55, 311-318.	1.8	12
81	Pseudomonas aeruginosa bloodstream infections: risk factors and treatment outcome related to expression of the PER-1 extended-spectrum beta-lactamase. BMC Infectious Diseases, 2006, 6, 52.	2.9	40
82	CTX-M-Type Extended-Spectrum \hat{I}^2 -Lactamases in Italy: Molecular Epidemiology of an Emerging Countrywide Problem. Antimicrobial Agents and Chemotherapy, 2006, 50, 2700-2706.	3.2	107
83	Spread of Enterobacteriaceae carrying the PER-1 extended-spectrum Â-lactamase gene as a chromosomal insert: a report from Italy. Journal of Antimicrobial Chemotherapy, 2006, 59, 323-324.	3.0	13
84	CMY-16, a Novel Acquired AmpC-Type Î ² -Lactamase of the CMY/LAT Lineage in Multifocal Monophyletic Isolates of Proteus mirabilis from Northern Italy. Antimicrobial Agents and Chemotherapy, 2006, 50, 618-624.	3.2	68
85	Use of the Phoenix Automated System for Identification of Streptococcus and Enterococcus spp Journal of Clinical Microbiology, 2006, 44, 3263-3267.	3.9	33
86	Microbiology of Postoperative Infections. Surgical Infections, 2006, 7, s-13-s-16.	1.4	8
87	Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia. BMC Infectious Diseases, 2005, 5, 106.	2.9	26
88	Proteus mirabilis Bloodstream Infections: Risk Factors and Treatment Outcome Related to the Expression of Extended-Spectrum \hat{l}^2 -Lactamases. Antimicrobial Agents and Chemotherapy, 2005, 49, 2598-2605.	3.2	130
89	Novel TEM-Type Extended-Spectrum \hat{l}^2 -Lactamase, TEM-134, in a Citrobacter koseri Clinical Isolate. Antimicrobial Agents and Chemotherapy, 2005, 49, 1564-1566.	3.2	15
90	Dissemination of CTX-M-Type Extended-Spectrum \hat{I}^2 -Lactamase Genes to Unusual Hosts. Journal of Clinical Microbiology, 2005, 43, 4183-4185.	3.9	18

#	Article	IF	Citations
91	Evolution of CTX-M-type \hat{l}^2 -lactamases in isolates of Escherichia coli infecting hospital and community patients. International Journal of Antimicrobial Agents, 2005, 25, 157-162.	2.5	94
92	Emergence in Klebsiella pneumoniae and Enterobacter cloacae Clinical Isolates of the VIM-4 Metallo-Î ² -Lactamase Encoded by a Conjugative Plasmid. Antimicrobial Agents and Chemotherapy, 2004, 48, 648-650.	3.2	103
93	Bacteremia Due toKlebsiella pneumoniaelsolates Producing the TEMâ€52 Extendedâ€Spectrum βâ€Lactamase: Treatment Outcome of Patients Receiving Imipenem or Ciprofloxacin. Clinical Infectious Diseases, 2004, 38, 243-251.	5. 8	105
94	Prevalence and characterization of metallo-l²-lactamases in clinical isolates of pseudomonas aeruginosa㘆. Diagnostic Microbiology and Infectious Disease, 2004, 48, 131-135.	1.8	31
95	Novel 3- N -Aminoglycoside Acetyltransferase Gene, aac (3)- Ic , from a Pseudomonas aeruginosa Integron. Antimicrobial Agents and Chemotherapy, 2003, 47, 1746-1748.	3.2	40
96	IMP-12, a New Plasmid-Encoded Metallo- \hat{l}^2 -Lactamase from a Pseudomonas putida Clinical Isolate. Antimicrobial Agents and Chemotherapy, 2003, 47, 1522-1528.	3.2	125
97	A two-year analysis of risk factors and outcome in patients with bloodstream infection. Japanese Journal of Infectious Diseases, 2003, 56, 1-7.	1.2	28
98	Clonal Diversity and Metallo- \hat{l}^2 -Lactamase Production in Clinical Isolates of Stenotrophomonas maltophilia. Microbial Drug Resistance, 2002, 8, 193-200.	2.0	23
99	Molecular Characterization of Extended-Spectrum Â-Lactamases Produced by Nosocomial Isolates of Enterobacteriaceae from an Italian Nationwide Survey. Journal of Clinical Microbiology, 2002, 40, 611-614.	3.9	116
100	Nosocomial Infections Caused by Multidrug-Resistant Isolates of Pseudomonas putida Producing VIM-1 Metallo-Î ² -Lactamase. Journal of Clinical Microbiology, 2002, 40, 4051-4055.	3.9	105
101	Biochemical Characterization of TEM-92 Extended-Spectrum β-Lactamase, a Protein Differing from TEM-52 in the Signal Peptide. Antimicrobial Agents and Chemotherapy, 2002, 46, 3981-3983.	3 . 2	6
102	Occurrence of Extended-Spectrum \hat{l}^2 -Lactamases in Members of the Family <i>Enterobacteriaceae</i> in Italy: Implications for Resistance to \hat{l}^2 -Lactams and Other Antimicrobial Drugs. Antimicrobial Agents and Chemotherapy, 2002, 46, 196-202.	3.2	144
103	Burkholderia cepacia complex in cystic fibrosis and non-cystic fibrosis patients: identification of a cluster of epidemic lineages. Journal of Hospital Infection, 2002, 50, 188-195.	2.9	29
104	Epidemiology of bloodstream infections and time to detection of positive blood cultures: an evaluation of the automated BacT/Alert and BACTEC 9240 systems. New Microbiologica, 2002, 25, 9-16.	0.1	12
105	Properties of multidrug-resistant, ESBL-producing Proteus mirabilis isolates and possible role of \hat{l}^2 -lactam/ \hat{l}^2 -lactamase inhibitor combinations. International Journal of Antimicrobial Agents, 2001, 17, 131-135.	2.5	46
106	Multidrug-Resistant < i > Pseudomonas aeruginosa < / i > Producing PER-1 Extended-Spectrum Serine-β-Lactamase and VIM-2 Metallo-β-Lactamase. Emerging Infectious Diseases, 2001, 7, 910-911.	4.3	40
107	Dynamics of a Nosocomial Outbreak of Multidrug-Resistant Pseudomonas aeruginosa Producing the PER-1 Extended-Spectrum \hat{l}^2 -Lactamase. Journal of Clinical Microbiology, 2001, 39, 1865-1870.	3.9	74
108	PER-1 Extended-Spectrum Î ² -Lactamase Production in anAlcaligenes faecalisClinical Isolate Resistant to Expanded-Spectrum Cephalosporins and Monobactams from a Hospital in Northern Italy. Microbial Drug Resistance, 2000, 6, 85-90.	2.0	45

#	Article	IF	CITATION
109	Comparative Activity of Piperacillin/Tazobactam against Clinical Isolates of Extended- Spectrum \hat{l}^2 -Lactamase-Producing Enterobacteriaceae. Chemotherapy, 1998, 44, 377-384.	1.6	14
110	Characterization of a new TEM-derived beta-lactamase produced in a Serratia marcescens strain. Antimicrobial Agents and Chemotherapy, 1997, 41, 2374-2382.	3.2	34
111	Extended-Spectrum β-Lactamases Conferring Resistance to Monobactams and Oxyimino-Cephalosporins in Clinical Isolates of Serratia marcescens. Journal of Chemotherapy, 1995, 7, 175-178.	1.5	8
112	Necrotizing Pneumonitis and Empyema Caused by Streptococcus cremoris from Milk. Scandinavian Journal of Infectious Diseases, 1990, 22, 221-222.	1.5	20